title: Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography.
abstract: OBJECTIVE
  To analyse the neointimal coverage of sirolimus-eluting stent (SES) and bare-metal stent (BMS) visualised in vivo by optical coherence tomography (OCT).
  
  
  METHODS
  OCT images were obtained in 26 coronary vessels of 24 patients at 5-93 months after SES or BMS deployment. The short-term BMS group (BMS1) consisted of eight BMS in seven patients at 5-10 months of follow-up, the long-term BMS group (BMS2) consisted of six BMS in six patients at 23-93 months of follow-up, and the SES group (SES) consisted of 13 SES in 10 patients at 6-12 months of follow-up. The strut apposition, strut coverage and mean maximal and minimal neointimal thicknesses (NIT) for both BMS groups and SES were compared.
  
  
  RESULTS
  OCT images were acquired successfully. Significant differences between completely apposed and malapposed stent struts (p<0.0001) and between covered and uncovered stent struts (p<0.0001) were found among the three groups. The mean maximal and minimal NIT in the SES group were all significantly less than those of the BMS1 or BMS2 group, the minimal NIT in the BMS1 group was significantly less than that of the BMS2 but the mean maximal NIT was no significant difference between the BMS1 and BMS2 groups. In an open bifurcation artery, 19 struts visualised by OCT had no discernible coverage or were surrounded by either thrombus or a thick tissue layer.
  
  
  CONCLUSIONS
  OCT imaging can clearly visualise stent apposition and neointimal coverage of stent struts. Incomplete strut apposition and lack of strut coverage occurred with a significantly higher frequency in SES than in BMS. These findings may explain the occurrence of late thrombosis in SES. Optical coherence tomography (OCT) is the optical analogue to ultrasound, measuring the back-reflection of infrared light instead of sound waves. The greatest advantage of OCT is its high resolution, which exceeds that of any currently available in vivo imaging technology. The resolution of catheter-based systems is in the range of 10-20 microm. Furthermore, resolutions as high as 4 microm have been achieved ex vivo with more sophisticated techniques that may be applicable to future catheter-based approaches. The main components of various atheromatous plaques can be identified in OCT images, and have been validated in a histology-controlled study. Several studies have demonstrated the feasibility of OCT imaging in patients undergoing percutaneous coronary intervention (PCI). The aim of the present study was to use OCT to analyse the neointimal coverage of sirolimus-eluting stents (SES), compared with that of bare-metal stents (BMS).
authors.affiliation: Department of Cardiology, Beijing Electric Power Hospital, Beijing, China. chbux@sohu.com
authors.forename: B X
authors.initials: BX
authors.lastname: Chen
authors.forename: F Y
authors.initials: FY
authors.lastname: Ma
authors.forename: W
authors.initials: W
authors.lastname: Luo
authors.forename: J H
authors.initials: JH
authors.lastname: Ruan
authors.forename: W L
authors.initials: WL
authors.lastname: Xie
authors.forename: X Z
authors.initials: XZ
authors.lastname: Zhao
authors.forename: S H
authors.initials: SH
authors.lastname: Sun
authors.forename: X M
authors.initials: XM
authors.lastname: Guo
authors.forename: F
authors.initials: F
authors.lastname: Wang
authors.forename: T
authors.initials: T
authors.lastname: Tian
authors.forename: X W
authors.initials: XW
authors.lastname: Chu
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D002404:Catheterization / Q000379:methods; D017023:Coronary Angiography / Q000379:methods; D003324:Coronary Artery Disease / Q000175:diagnosis* / Q000628:therapy; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents; D041623:Tomography, Optical Coherence / Q000379:methods; D016896:Treatment Outcome; D017539:Tunica Intima / Q000254:growth & development*
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus